Impact of resolved hepatitis B virus infection on clinical outcomes in patients with diffuse large B-cell lymphoma: a supplementary analysis of JCOG0601.
Past hepatitis B infection doesn't worsen outcomes in lymphoma patients treated with standard immunochemotherapy, offering reassurance to this population.
The impact of resolved hepatitis B virus (HBV) infection, defined as pretreatment hepatitis B surface antigen (HBsAg) negativity with antibody to hepatitis B core antigen (anti-HBc) positivity, on the clinical characteristics and outcomes of diffuse large B-cell lymphoma (DLBCL) remains unclear. Baseline anti-HBc positivity was more common in older patients but was not associated with inferior outcomes in HBsAg-negative DLBCL treated with rituximab-containing CHOP-based therapy.Clinical trial registration: JCOG0601 was registered in the Japan Registry of Clinical Trials (jRCTs031180139, date of registration; February 20, 2019).
What the study was
- Study design
- Supplementary analysis of randomized phase II/III trial (JCOG0601)
- Population
- Previously untreated DLBCL patients with resolved HBV infection
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- International journal of hematology
Why it surfaced
Uses RCT data (JCOG0601) to clarify impact of resolved HBV on DLBCL outcomes; clinically important for managing anti-viral prophylaxis decisions in lymphoma.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.